Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. BiomX Inc.
  6. News
  7. Summary
    PHGE   US09090D1037

BIOMX INC.

(PHGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BIOMX INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/16/2021 | 10:06am EDT

Item 2.02 Results of Operations and Financial Condition.

On August 16, 2021, BiomX Inc., or the Company, issued a press release announcing its financial results for the second quarter ended June 30, 2021. A copy of the press release issued in connection with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit   Description

99.1        Press Release dated August 16, 2021




                                       1

© Edgar Online, source Glimpses

All news about BIOMX INC.
10/25BiomX Inc. announced that it has received $3 million in funding
CI
10/19BIOMX : Chardan Adjusts Price Target on BiomX to $16 From $28 After "Disappointing" Drug T..
MT
10/18BIOMX : HC Wainwright Adjusts BiomX Price Target to $10 From $20, Maintains Buy Rating
MT
10/18BIOMX : Says 'No Meaningful Differentiation' in Efficacy Between BX001 Acne Treatment and ..
MT
10/18BIOMX INC. : Other Events (form 8-K)
AQ
10/18BIOMX : Reports Topline Results of Phase 2 Cosmetic Acne Study
GL
10/18BiomX Inc. Reports Topline Results of Phase 2 Cosmetic Acne Study
CI
10/14BiomX Inc. announced that it expects to receive $3 million in funding
CI
10/13BIOMX : Enters Agreement to Grant Maruho Right of First Offer to License Eczema Drug in Ja..
MT
10/13BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate..
GL
More news
Analyst Recommendations on BIOMX INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,79x
Yield 2021 -
Capitalization 64,3 M 64,3 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 101
Free-Float 79,6%
Chart BIOMX INC.
Duration : Period :
BiomX Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,28 $
Average target price 14,50 $
Spread / Average Target 536%
EPS Revisions
Managers and Directors
Jonathan Eithan Solomon Chief Executive Officer & Director
Marina Wolfson Vice President-Finance & Operations
Russell G. Greig Chairman
Sailaja Puttagunta Chief Medical Officer
Gbola Amusa Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOMX INC.-64.58%64
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.20.76%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753